Evidence map›Paper›PMID 26787754›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Samira A Brooks, Amir H Khandani, Julia R Fielding, Weili Lin, Tiffany Sills, Yueh Lee, Alexandra Arreola, Mathew I Milowsky, Eric M Wallen, Michael E Woods and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Heterogeneity Metabolism of Renal Cell Carcinomas.Advances in experimental medicine and biology · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Review
  12. Article
  13. Review
  14. Article
  15. Renal cell carcinoma: new insights and challenges for a clinician scientist.American journal of physiology. Renal physiology · 2017
    Review
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Samira A BrooksUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Amir H KhandaniDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina. Department of Radiology, Nuclear Medicine, University of North Carolina at Chapel Hill, North Carolina. kimryn.rathmell@vanderbilt.edu khandani@med.unc.edu.
Julia R FieldingDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Weili LinDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Tiffany SillsDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Yueh LeeDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Alexandra ArreolaUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Mathew I MilowskyUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Eric M WallenUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Michael E WoodsDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Angie B SmithDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Mathew E NielsenDepartment of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Joel S ParkerUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
David S LalushDepartment of Radiology, Nuclear Medicine, University of North Carolina at Chapel Hill, North Carolina. Joint Department of Biomedical Engineering, The University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, Raleigh, North Carolina.
W Kimryn RathmellUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. kimryn.rathmell@vanderbilt.edu khandani@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
TOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0M
Translational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0M
Enhancing Translational Science via Prospective InvestigationK24CA172355 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RATHMELL, WENDY KIMRYN · 2013 to 2017
$870k
NCI NIH HHS K24 CA172355NCI NIH HHS P30 CA016086NCI NIH HHS T32 CA160001NIEHS NIH HHS P30 ES010126NIEHS NIH HHS T32 ES007126
6 · The paper itself

Abstract

purposeClear cell renal cell carcinoma (ccRCC) has recently been redefined as a highly heterogeneous disease. In addition to genetic heterogeneity, the tumor displays risk variability for developing metastatic disease, therefore underscoring the urgent need for tissue-based prognostic strategies applicable to the clinical setting. We have recently employed the novel PET/magnetic resonance (MR) image modality to enrich our understanding of how tumor heterogeneity can relate to gene expression and tumor biology to assist in defining individualized treatment plans. EXPERIMENTAL

designccRCC patients underwent PET/MR imaging, and these images subsequently used to identify areas of varied intensity for sampling. Samples from 8 patients were subjected to histologic, immunohistochemical, and microarray analysis.

resultsTumor subsamples displayed a range of heterogeneity for common features of hypoxia-inducible factor expression and microvessel density, as well as for features closely linked to metabolic processes, such as GLUT1 and FBP1. In addition, gene signatures linked with disease risk (ccA and ccB) also demonstrated variable heterogeneity, with most tumors displaying a dominant panel of features across the sampled regions. Intriguingly, the ccA- and ccB-classified samples corresponded with metabolic features and functional imaging levels. These correlations further linked a variety of metabolic pathways (i.e., the pentose phosphate and mTOR pathways) with the more aggressive, and glucose avid ccB subtype.

conclusionsHigher tumor dependency on exogenous glucose accompanies the development of features associated with the poor risk ccB subgroup. Linking these panels of features may provide the opportunity to create functional maps to enable enhanced visualization of the heterogeneous biologic processes of an individual's disease. Clin Cancer Res; 22(12); 2950-9. ©2016 AACR.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellDisease ProgressionGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMagnetic Resonance ImagingMicroarray AnalysisPositron Emission Tomography Computed TomographyBiomarkers, Tumor

Identifiers

PMID26787754
PMCPMC4911278
OpenAlexW2275094380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.